Virtu Financial LLC Acquires New Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Virtu Financial LLC bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,033 shares of the company’s stock, valued at approximately $102,000.

Other hedge funds also recently added to or reduced their stakes in the company. Candriam S.C.A. acquired a new stake in shares of iTeos Therapeutics in the 2nd quarter worth about $7,558,000. State Street Corp increased its stake in shares of iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after purchasing an additional 211,452 shares during the period. Clearline Capital LP acquired a new stake in shares of iTeos Therapeutics in the second quarter valued at approximately $2,328,000. Algert Global LLC raised its holdings in shares of iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after buying an additional 122,730 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after buying an additional 117,159 shares during the period. 97.16% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Matthew Gall acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

ITOS has been the topic of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research note on Friday, December 13th. Finally, Wells Fargo & Company reduced their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $7.22 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $7.12 and a 1 year high of $18.75. The stock has a fifty day moving average price of $8.59 and a two-hundred day moving average price of $12.71. The firm has a market cap of $263.78 million, a P/E ratio of -2.29 and a beta of 1.37.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.13. On average, research analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.